CA125 Cancer Antigen

Added to your cart

CA125 Cancer Antigen

Cart subtotal: £0.00

View cart (0) Checkout

#SKU P251-4

£99.60

Price excludes shipping costs.
To view our shipping costs click here.

Need to order this product in bulk?

Contact our team of experts to discuss your bulk requirements

Contact our expert team

Product Details

CA125 is an antigen found in ovarian cells. When the ovarian cells become cancerous raised CA125 levels are observed and are released into the bloodstream. The CA125 marker is used primarily for assessment of but also in conjunction with HE4 diagnosis of ovarian cancer. Why should you choose BBI's CA125 antigen: Sourced from a stable cell-line for supply consistency Low cross reactivity with other tumour markers Tested on multiple platforms showing excellent recovery Tried and trusted - used by key IVD companies in controls and calibrators Our production facilities allow us to offer consistent and reproducible large batch sizes up to thousands of Ku With a network of global labs and hospitals, we can access many diverse testing platforms, providing you with the exact analysis results you need We can adapt dispensations to meet your needs

20 Ku
P251-4

More information

Attributes

Description

  • Shipping Information
  • Dry Ice
  • Abbreviations
  • CA125
  • Specification
  • > 250 Ku/ml CA125
  • Recommended Use
  • Research and further manufacturing
  • Preservatives
  • 0.09% NaN3
  • Buffer
  • 0.05M sodium phosphate buffer, pH 7.5 containing 0.15M NaCl
  • Presentation Matrix
  • 0.05M phosphate buffer, pH 7.5 containing 0.15M NaCl and 0.09% NaN3
  • Purity/grade
  • Low Cross Contamination, >250 Ku/mL
  • Source
  • Human Cell Line
  • Applications
  • Biosensors, Clinical Chemistry, Control Manufacture, ELISA, Lateral Flow, Life Science
  • Molecular weight
  • 200 - 1000 kDa

Technical Documents

Certificates Of Analysis (80.42KB)

Sorry, no results found.

Enter the full lot number and hit enter.

BBI Solutions Brands

diarect.png

The acquisition of DIARECT in June 2020 and their world leading recombinant autoimmune antigen capability immediately enhances BBI’s portfolio and position as a ‘complete’ immunoassay reagent supplier. This further enhances BBI’s position as the world’s largest diagnostics components company with a market leading antigen portfolio.

mbs.png

Maine Biotechnology Services brings 27 years of knowledge, experience, process development, and project management to our customers to ensure the best possible antibodies for any application. As antibody development goals in the biotechnology and pharmaceutical industry have evolved the acquisition of MBS will help BBI further meet and exceed our customers needs.

Newsletter

Signup for our newsletter to receive the latest BBI Solutions updates and special offers in your inbox